Abstracts tagged "Biomarkers"

Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0341 • ACR Convergence 2025
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Daniel Ramos Castro¹, SAMUEL LEAL², ELENA GRAU GARCIA³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Andres perez Hurtado⁹, Miguel Simeo Vinaixa⁹ and José Andrés Román Ivorra¹⁰, ¹Hospital Universitari i Politecnic La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is the most common bone metabolism disorder in developed countries. It increases the risk of fragility fractures, impairing quality of life, increasing disability,…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 2530 • ACR Convergence 2025
Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
Federica Bonaso¹, Bohang Jiang², Laura J. Yockey³, Jesse Akaa⁴, Ian Doyle⁴, Evan Hsu⁵, Courtney Leson⁶, Grace McMahon⁷, Isha Jha⁷, Sydney Montesi⁷, Guy Katz⁷, Shiv Pillai⁸, Pui Lee⁵, John Stone⁹, Zachary Wallace¹⁰ and Cory Perugino¹¹, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²MGH, Boston, MA, ³MGH, Charlestown, MA, ⁴Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ⁵Boston Children's Hospital, Newton, MA, ⁶Boston Children's Hospital, Boston, ⁷Massachusetts General Hospital, Boston, MA, ⁸Harvard Medical School, Cambridge, MA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ¹⁰Massachusetts General Hospital, Newton, MA, ¹¹Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterized by mass-forming lesions and organ dysfunction. The smoldering tempo and often asymptomatic nature of IgG4-RD…
Abstract Number: 2310 • ACR Convergence 2025
Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
ELENA GRAU GARCIA¹, SAMUEL LEAL², Jose Ivorra Cortes³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Daniel Ramos Castro⁶, Alba Maria Torrat Noves⁷, Iago Alcantara Alvarez⁸, Belen Villanueva Manes⁹, Miguel Simeo Vinaixa⁸, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Spain, ⁹Hospital La Fe, València, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: NGFβ and CGRP are neuropeptides with a significant role in peripheral inflammation, pain modulation and immune responses. Neuropeptides regulatory mechanisms in spondyloarthritis (SpA) remain…
Abstract Number: 2073 • ACR Convergence 2025
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Sabína Oreská¹, Kristina Svobodová¹, Lucia Vernerová¹, Dana Dlouhá², Hana Wunsch¹, Karel Pavelka¹, Jiri Vencovsky³, Ladislav Šenolt⁴, Michal Vrablik⁵, Jaroslav Alois Hubáček² and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…
Abstract Number: 1811 • ACR Convergence 2025
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Mariana Correia Marques¹, Michael Matt², Sophia Chou³, Peter Burbelo⁴, Zuoming Deng⁵, George Tomlinson⁶, Yukiko Kimura⁷, Grant Schulert² and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁴Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶University of Toronto, Toronto, ON, Canada, ⁷Hackensack Meridian School of Medicine, New York, NY, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
Abstract Number: 1680 • ACR Convergence 2025
Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Alen Zabotti¹, Valeria Manfrè¹, Maria Teresa Rizzo¹, Alessia Nano¹, Garifallia Sakellariou² and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy
Background/Purpose: Sjögren's disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features…
Abstract Number: 1436 • ACR Convergence 2025
Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Devy Zisman¹, Amir Haddad², Dunia Araide³, Noa Hayat², Tal Gazitt⁴, Joy Feld⁵, Michal Aizenberg Peleg¹, Muhanad Abu-Elhija¹, Ameen Batheesh¹, Abdulla Watad⁶, Alina Simanovich¹, Nili Stein¹, Kateryna Milman² and Michal Amit Rahat¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, HaZafon, Israel, ⁴Carmel Hospital, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel, ⁶Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Difficult to treat (D2T) psoriatic arthritis (PsA) presents a state of active inflammatory disease manifestations despite therapy with at least two biologic disease modifying…
Abstract Number: 1208 • ACR Convergence 2025
Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Jia Shi¹, Yang Wu², Aviya Levy³, Ting Wang⁴, Abhinav Janappareddi⁵, Payton Hermanson¹, Jorge A. Gonzalez-Chapa⁵, Qian Wang⁶, Susan Shenoi⁷ and Christian Lood⁵, ¹University of Washington, Seattle, WA, ²¹. Chinese Academy of Medical Sciences & Peking Union Medical College; ². Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China; ³. University of Washington, Division of Rheumatology, Seattle, WA, USA, Beijing, China (People's Republic), ³Rady Children's Hospital, San Diego, CA, ⁴Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, ⁵University of Washington, Division of Rheumatology, Seattle, ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
CHEN-YU LEE¹, Sepehr Taghavi², Shangzhu Zhang³, Roopa Madhu⁴, Jasmine Shwetar⁵, Tyler O'Malley⁶, Daniel Goldman⁷, Peter Izmirly⁸, H Michael Belmont⁹, Richard Furie¹⁰, Noa Schwartz¹¹, Chaim Putterman¹², Jennifer Barnas¹³, Jennifer Anolik¹⁴, Sarah French¹⁵, Maria Dall'Era¹⁶, Judith James¹⁷, Joel Guthridge¹⁷, Jacob Vasquez¹⁸, Mike Nerenberg¹⁹, Andrew Concoff²⁰, Christine Schleif²¹, Kevin Wei²², Thomas Eisenhaure²³, Nir Hacohen²³, Rachael Bogle²⁴, Johann Gudjonsson²⁵, Lam Tsoi²⁵, Brad Rovin²⁶, Jill Buyon²⁷, Michelle Petri⁷ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Exagen Inc, Escondido, CA, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Brookline, MA, ⁵New York School of Medicine, Ann Arbor, MI, ⁶Exagen, Vista, CA, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰Division of Rheumatology, Northwell Health, Great Neck, NY, ¹¹Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ¹²Albert Einstein College of Medicine, Safed, Israel, ¹³University of Rochester, Rochester, NY, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵UCSF, Mill Valley, CA, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Exagen, Inc., Vista, CA, ¹⁹Exagen, DEL MAR, CA, ²⁰Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, ²¹Exagen, Carlsbad, CA, ²²Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²³Broad Institute, Cambridge, MA, ²⁴University of Michigan, Holland, OH, ²⁵University of Michigan, Ann Arbor, MI, ²⁶The Ohio State University, Columbus, OH, ²⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…

« Previous Page
1
…
4
5
6
7
8
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].